Aktuelle und neue Medikamente in der Tabakentwöhnung

B. Kusma; S. Mache; F. Deissenrieder; D. Quarcoo; T. Welte; D. Groneberg

doi:10.1055/s-2008-1038270

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000059.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Pneumologie 2008; 62(12): 718-729
DOI: 10.1055/s-2008-1038270

Fort- und Weiterbildung

Aktuelle und neue Medikamente in der Tabakentwöhnung

Current and Future Medical Drugs for Smoking CessationB. Kusma^1, ² , S. Mache¹ , F. Deissenrieder¹ , D. Quarcoo¹ , T. Welte² , D. Groneberg¹

¹Institut für Arbeitsmedizin, Charité Universitätsmedizin Berlin (Direktor: Univ.-Prof. Dr. D. Groneberg)
²Abteilung Pneumologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover (Direktor: Univ.-Prof. Dr. T. Welte)

Further Information

Publication History

Publication Date:
02 December 2008 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Lerninhalte

Grundlagenwissen zur Epidemiologie und Auswirkungen von Tabakkonsum Grundlagenwissen zur neurobiologischen Wirkung des Rauchens Definition von Tabaksucht Differenzierte Beschreibung der Therapieformen der Tabakentwöhnung, Vergleich von pharmakologischen und verhaltenstherapeutischen Ansätzen

Literatur

1 World Health Organization .The facts about smoking and health. 2006

Google Scholar
2 Becker N, Wahrendorf J H. Krebsatlas der Bundesrepublik Deutschland 1981 – 1990. Heidelberg: Springer 1998

Google Scholar
3 Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GKID) .Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken: Krebsregister 2006

Google Scholar
4 Deutsches Krebsforschungszentrum (DKFZ) .Passivrauchende Kinder in Deutschland – Frühe Schädigungen für ein ganzes Leben. Heidelberg 2003

Google Scholar
5 US Department of Health and Human Services .The health benefits of smoking cessation: A report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, Center for Chronic Disease Prevention and Health Promotion, Public Health Service, Office on Smoking and Health 1990

Google Scholar
6 Balfour D J, Fagerstrom K O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther. 1996; 72 51-81

Google Scholar
7 Balfour D J, Benwell M E, Birrell C E. et al . Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol Biochem Behav. 1998; 59 1021-1030

Google Scholar
8 Pomerleau O F. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med. 1992; 93 2S-7S

Google Scholar
9 Epping-Jordan M P, Watkins S S, Koob G F. et al . Dramatic decreases in brain reward function during nicotine withdrawal. Nature. 1998; 393 76-79

Google Scholar
10 Picciotto M R, Zoli M, Rimondini R. et al . Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998; 391 173-177

Google Scholar
11 Furtado R. Implicações anestésicas do tabagismo. Rev Bras Anestesiol. 2002; 52 354-367

Google Scholar
12 Batra A. Tabakabhängigkeit. Biologische und psychosoziale Entstehungsbedingungen und Therapiemöglichkeiten. Darmstadt: Steinkopf 2000

Google Scholar
13 Marques A CPR. et al . Consenso sobre o tratamento da dependência de nicotina. Rev Bras Psiquiatr. 2001; 23 200-214

Google Scholar
14 US Department of Health and Human Services .The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. Rockville, Maryland 1988

Google Scholar
15 Dilling H, Monbour W, Schmidt M H. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F). Göttingen: Huber 1991

Google Scholar
16 Saß H, Wittchen H U, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen DSM IV. Göttingen, Bern, Toronto, Seattle: Hogrefe 1996

Google Scholar
17 Batra A, Fagerström K O. Neue Aspekte der Nikotinabhängigkeit und Raucherentwöhnung. Sucht. 1997; 43 277-282

Google Scholar
18 Breslau N, Johnson E O, Hiripi E. et al . Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Arch Gen Psychiatry. 2001; 58 810-816

Google Scholar
19 World Health Organization .Tobacco or health: a global status report. Geneva: World Health Organization 1997

Google Scholar
20 Fagerstrom K O, Schneider N G. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989; 12 159-182

Google Scholar
21 Lagrue G, Lafnoune N, Cormier S. et al . Urinary cotinine-creatinine ratio as a marker of nicotine intake: a guide for the nicotine replacement therapy during smoking cessation. Congrès annuel ERS, Florence 1993. Eur Respir J. 1993; 6

Google Scholar
22 Fiore M C, Bailey W C, Cohen S J. Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service 2000

Google Scholar
23 Haustein K O. Pharmacotherapy of nicotine dependence. Int J Clin Pharmacol Ther. 2000; 38 273-290

Google Scholar
24 Henningfield J E. Nicotine medications for smoking cessation. N Engl J Med. 1995; 333 1196-1203

Google Scholar
25 Mühling S, Nowak D. 9 Thesen zur Raucherentwöhnung. Suchtmed. 2004; 6

Google Scholar
26 Nowak D, Hoch E. Raucherentwöhnung – Pharmakologie, Effizienz und Hemmnisse. Bay Int. 2005; 25 118-126

Google Scholar
27 Schön S, Nowak D. Medikamentöse Verfahren zur Raucherentwöhnung. Suchtmed. 2002; 4 189-199

Google Scholar
28 Silagy C, Lancaster T, Stead L. et al . Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004; CD000146

Google Scholar
29 Henningfield J E, Fant R V, Buchhalter A R. et al . Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005; 55 281-299; quiz 322 – 283, 325

Google Scholar
30 Mitrouska I, Bouloukaki I, Siafakas N M. Pharmacological approaches to smoking cessation. Pulm Pharmacol Ther. 2007; 20 220-232

Google Scholar
31 Wu P, Wilson K, Dimoulas P. et al . Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006; 6 300

Google Scholar
32 Fiore M C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care. 2000; 45 1196-1199

Google Scholar
33 Hjalmarson A, Franzon M, Westin A. et al . Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med. 1994; 154 2567-2572

Google Scholar
34 Sutherland G, Stapleton J A, Russell M A. et al . Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992; 340 324-329

Google Scholar
35 Sutherland G, Russell M A, Stapleton J. et al . Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology (Berl). 1992; 108 512-518

Google Scholar
36 Choi J H, Dresler C M, Norton M R. et al . Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res. 2003; 5 635-644

Google Scholar
37 Shiffman S, Dresler C M, Hajek P. et al . Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002; 162 1267-1276

Google Scholar
38 Blondal T, Gudmundsson L J, Olafsdottir I. et al . Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. Bmj. 1999; 318 285-288

Google Scholar
39 Bohadana A, Nilsson F, Rasmussen T. et al . Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000; 160 3128-3134

Google Scholar
40 Kornitzer M, Boutsen M, Dramaix M. et al . Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995; 24 41-47

Google Scholar
41 Benowitz N L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008; 83 531-541

Google Scholar
42 Hays J T, Ebbert J O. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits. CNS Drugs. 2003; 17 71-83

Google Scholar
43 Slemmer J E, Martin B R, Damaj M I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000; 295 321-327

Google Scholar
44 Hurt R D, Sachs D P, Glover E D. et al . A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997; 337 1195-1202

Google Scholar
45 Lee A M, Jepson C, Hoffmann E. et al . CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry. 2007; 62 635-641

Google Scholar
46 Jorenby D E, Leischow S J, Nides M A. et al . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340 685-691

Google Scholar
47 Hughes J R, Stead L F, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007; CD000031

Google Scholar
48 Roddy E. Bupropion and other non-nicotine pharmacotherapies. Bmj. 2004; 328 509-511

Google Scholar
49 George T P, O'Malley S S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci. 2004; 25 42-48

Google Scholar
50 Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002; 62 Suppl 2 5-35

Google Scholar
51 Aubin H J. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs. 2002; 62 Suppl 2 45-52

Google Scholar
52 Settle Jr E C. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998; 59 Suppl 4 32-36

Google Scholar
53 da Costa C L, Younes R N, Lourenco M T. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest. 2002; 122 403-408

Google Scholar
54 Hall S M, Reus V I, Munoz R F. et al . Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998; 55 683-690

Google Scholar
55 Ferry L H. Non-nicotine pharmacotherapy for smoking cessation. Prim Care. 1999; 26 653-669

Google Scholar
56 Abbot N C, Stead L F, White A R. et al . Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2000; CD001008

Google Scholar
57 Prochazka A V, Kick S, Steinbrunn C. et al . A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med. 2004; 164 2229-2233

Google Scholar
58 Gourlay S G, Stead L F, Benowitz N L. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004; CD000058

Google Scholar
59 Jorenby D E, Hays J T, Rigotti N A. et al . Efficacy of varenicline, an alpha-4-beta-2-nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama. 2006; 296 56-63

Google Scholar
60 Cohen C, Perrault G, Voltz C. et al . SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002; 13 451-463

Google Scholar
61 Anthenelli R, Despres J. Effects of rimonabant in the reduction of major car-diovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Presented at Am. College Cardiol. 53rd Annu. Sci. Session. New Orleans, LA: Rapid News Summaries 2004

Google Scholar
62 Anthenelli R. Rimonabantin smoking abstinence: the STRATUS-programm. in Proc. 11 Annu. Meet. Soc. Res. Nicotine Tobacco. Prague, Czech 2005

Google Scholar
63 EMEA .Questions and answers on the safety of Acomplia (Rimonabant). http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-qa.pdf. London: European Medicines Agency 2007

Google Scholar
64 Cerny T. Anti-nicotine vaccination: where are we?. Recent Results Cancer Res. 2005; 166 167-175

Google Scholar
65 Hieda Y, Keyler D E, Ennifar S. et al . Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000; 22 809-819

Google Scholar
66 Pentel P R, Malin D H, Ennifar S. et al . A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000; 65 191-198

Google Scholar
67 Le Houezec J. Why a nicotine vaccine?. Clin Pharmacol Ther. 2005; 78 453-455

Google Scholar
68 LeSage M G, Keyler D E, Pentel P R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. Aaps J. 2006; 8 E65-75

Google Scholar
69 Lindblom N, de Villiers S H, Kalayanov G. et al . Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration. 2002; 69 254-260

Google Scholar
70 Cytos Biotechnology .Impfstoff zur Behandlung der Nikotinsucht fördert anhaltende Abstinenz während 12 Monaten bei Probanden mit hohen Antikörperwerten. http://www.cytos.com/doc/Cytos_Press_D_051 117.pdf. Schlieren: Cytos Biotechnology AG 2005

Google Scholar
71 Hatsukami D K, Rennard S, Jorenby D. et al . Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005; 78 456-467

Google Scholar
72 Maurer P, Jennings G T, Willers J. et al . A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005; 35 2031-2040

Google Scholar
73 White A R, Rampes H, Campbell J L. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2006; CD000009

Google Scholar
74 Balbani A, Montovani J. Methods for smoking cessation and treatment of nicotine dependence. Rev Bras Otorrinolaringol. 2005; 71 820-827

Google Scholar
75 Villano L M, White A R. Alternative therapies for tobacco dependence. Med Clin North Am. 2004; 88 1607-1621

Google Scholar
76 Stead L F, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2002; CD001007

Google Scholar
77 West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000; 55 987-999

Google Scholar
78 Deutsche Hauptstelle gegen die Suchtgefahren e. V. (DHS) .Frau SUCHT Gesundheit. Die Luft anhalten oder: Warum rauchen Frauen?. http://www.dhs.de/makeit/cms/cms_upload/dhs/die_luft_anhalten_low.pdf Hamm 2000

Google Scholar

Dipl. Psych. Bianca Kusma

Institut für Arbeitsmedizin

Thielallee 69 – 73

14159 Berlin

Email: bianca.kusma@charite.de